Picture loading failed.

Pre-Made Roledumab biosimilar, Whole mAb, Anti-RHD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-490-1mg 1mg 3090
GMP-Bios-ab-490-10mg 10mg Inquiry
GMP-Bios-ab-490-100mg 100mg Inquiry
GMP-Bios-ab-490-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Roledumab biosimilar, Whole mAb, Anti-RHD Antibody: Anti-CD240D/DIIIc/HDFNRH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhII/RhK562-II/RhPI therapeutic antibody
INN Name Roledumab
TargetRHD
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesLFB Biotechnologies
Conditions Approvedna
Conditions ActiveHaemolytic disease of newborn
Conditions Discontinuedna
Development TechEMABling Platform